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Background
In recent years, MRI and US have been increasingly
used as outcome measures in clinical trials in rheuma-
toid arthritis; their value in evaluating treatment efficacy
has never been tested in juvenile idiopathic arthritis
(JIA).
Aim
To compare conventional measures with MRI and US in
the assessment of treatment efficacy in JIA.
Methods
Patients with JIA and active wrist arthritis who started
receiving a second line therapy (DMARDs or biological
agent) at the study Unit between 2008 and 2010 were
enrolled in the study. The clinically more affected wrist
was studied with MRI (1.5 T), US and conventional
radiography (CR), coupled with standard clinical assess-
ment at the study enrollment and after 1 year. Patients
were characterized according to the pACR response cri-
teria, and to the current criteria for inactive disease.
Results
Thirty seven patients (median age 10.8 years, median
disease duration 4.1 years) were enrolled. Thirteen
patients out of 37 patients (35.1%) started DMARDs
while 24/37 patients (64.8%) started biologic agents.
Patients who met the definition of improvement accord-
ing to the pACR90 criteria (N=13) showed a signifi-
cantly greater decrease in MRI synovitis score compared
to patients who met the pACR 30, 50 and 70 criteria
(N=14) (p<0.0023), and compared to the non-responders
(N=10) (p<0.002), indicating the ability of MRI synovitis
score to discriminate between different levels of respon-
der categories. Excluding physician’s global assessment
of disease activity, MRI synovitis score was more
responsive (SRM 1.61) than ACR core set measures and
US synovitis score (SRM gray scale 0.87; SRM Doppler
0.71). After 1 year 11/37 patients met the critera for
inactive disease. Of these, only 1 showed no synovitis
according to MRI and 4 according to US. MRI and CR
performed equally in detecting structural damage pro-
gression after 1 year.
Conclusions
The excellent responsiveness and discriminant ability of
MRI synovitis score makes it promising as an outcome
measure in clinical studies. Only the high degree
responders showed a significant decrease in synovitis
score. Clinical criteria are insensitive to detect low level
of inflammation accurately, suggesting the potential role
of imaging in the assessment of remission.
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